You do not have permission to edit this page, for the following reasons:

This IP address has been blocked from editing Wikipedia.
This does not affect your ability to read Wikipedia pages.
Most people who see this message have done nothing wrong. Some kinds of blocks restrict editing from specific service providers or telecom companies in response to recent abuse or vandalism, and can sometimes affect other users who are unrelated to that abuse. Review the information below for assistance if you do not believe that you have done anything wrong.

The IP address or range 44.197.0.0/16 has been blocked (disabled) by ‪Blablubbs‬ for the following reason(s):

The IP address that you are currently using has been blocked because it is believed to be a web host provider or colocation provider. To prevent abuse, web hosts and colocation providers may be blocked from editing Wikipedia.
You will not be able to edit Wikipedia using a web host or colocation provider because it hides your IP address, much like a proxy or VPN.
We recommend that you attempt to use another connection to edit. For example, if you use a proxy or VPN to connect to the internet, turn it off when editing Wikipedia. If you edit using a mobile connection, try using a Wi-Fi connection, and vice versa. If you are using a corporate internet connection, switch to a different Wi-Fi network. If you have a Wikipedia account, please log in.
If you do not have any other way to edit Wikipedia, you will need to request an IP block exemption.

How to appeal if you are confident that your connection does not use a colocation provider's IP address:
If you are confident that you are not using a web host, you may appeal this block by adding the following text on your talk page: ((unblock|reason=Caught by a colocation web host block but this host or IP is not a web host. My IP address is _______. Place any further information here. ~~~~)). You must fill in the blank with your IP address for this block to be investigated. Your IP address can be determined here. Alternatively, if you wish to keep your IP address private you can use the unblock ticket request system. There are several reasons you might be editing using the IP address of a web host or colocation provider (such as if you are using VPN software or a business network); please use this method of appeal only if you think your IP address is in fact not a web host or colocation provider.

Administrators: The IP block exemption user right should only be applied to allow users to edit using web host in exceptional circumstances, and requests should usually be directed to the functionaries team via email. If you intend to give the IPBE user right, a CheckUser needs to take a look at the account. This can be requested most easily at SPI Quick Checkuser Requests. Unblocking an IP or IP range with this template is highly discouraged without at least contacting the blocking administrator.

This block will expire on 10:52, 20 August 2024.

Even when blocked, you will usually still be able to edit your user talk page, as well as email administrators and other editors.

For information on how to proceed, please read the FAQ for blocked users and the guideline on block appeals. The guide to appealing blocks may also be helpful.

Other useful links: Blocking policy · Help:I have been blocked
Your IP address is in a range that has been blocked on all Wikimedia Foundation wikis. The block was made by ‪AntiCompositeNumber‬. The reason given is Open proxy/Webhost: Visit the FAQ if you are affected .
- Start of block: 13:55, 18 August 2022
- Expiry of block: 13:55, 18 November 2024
Your current IP address is 44.197.119.13. The blocked range is 44.197.0.0/16. Please include all above details in any queries you make. If you believe you were blocked by mistake, you can find additional information and instructions in the No open proxies global policy. Otherwise, to discuss the block please post a request for review on Meta-Wiki. You could also send an email to the stewards VRT queue at stewards@wikimedia.org including all above details.

You can view and copy the source of this page:

((Short description|American biotechnology company))
((Verification|date=August 2022))
((Infobox company
| name = Avax Technologies
| logo = Avax Logo.PNG
| type = [[Public company|Public]]
| traded_as = ((OTC Expert|AVXT))
| genre = 
| foundation = <!--modifies "Founded" entry-->
| founder = 
| location_city = [[Philadelphia, Pennsylvania]]
| location_country = [[United States]]
| location = <!--modifies "Headquarters" entry-->
| locations = <!--# of locations-->
| origins = 
| key_people = ((nowrap | Richard Rainey <small>([[Chairman]] and [[Chief executive officer|CEO]])</small>))
| area_served = 
| industry = [[Biomedicine]]
| products = AC Vaccine
| services = [[Cancer vaccines]]
| revenue = 
| operating_income = 
| net_income = 
| num_employees = 
| parent = 
| divisions = 
| subsid = Genopoietic SA
| owner = 
| caption = 
| homepage = 
| dissolved = 
| footnotes = 
| intl = <!--Enter ''yes'' to change labels to international instead of US terminology-->
))
'''Avax Technologies, Inc''' is a [[Philadelphia]]-based [[biotechnology]] company whose most advanced product candidate is MVax for [[melanoma]]. MVax is a [[cancer vaccine]] that received a Special Protocol Assessment agreement with the [[Food and Drug Administration|FDA]] in October 2006, and subsequently began a Phase III registration clinical trial in November 2007. In previous studies, MVax demonstrated a [[Five-year survival rate|5-year overall survival rate (OS)]]of 44% and [[response rate (medicine)|response rate]] of 35% (13% CR, 22% PR).<ref name="Avax fact sheet">((cite web|url=http://www.avax-tech.com/about/pdfs/avaxfactsheet.pdf |title=Avax fact sheet Phase II data |url-status=dead |archiveurl=https://web.archive.org/web/20090206094105/http://avax-tech.com/about/pdfs/avaxfactsheet.pdf |archivedate=2009-02-06 ))</ref>

==AC Vaccine==

===Method===
A tumor sample is removed from a patient, then treated with the [[hapten]] [[2,4-Dinitrophenol]]. When reinjected back into the patient, the hapten will cause an enhanced immune response against the cancer cells.((Citation needed|date=April 2020))

===Product Candidates===

====MVax====
Started May 2007. Currently in a Phase III trial for Stage IV [[Melanoma]].

MVax’s Phase II response rate of 35% (CR + PR) in combination with low-dose IL-2 compares favorably to the Phase II results of other melanoma cancer vaccines such as Vical’s Allovectin-7 (11% CR + PR)<ref name="Allovectin-7">((cite web|url=http://www.vical.com/products/cancer_therapies/allovectin-7.htm |title=Allovectin-7 Phase II data |url-status=dead |archiveurl=https://web.archive.org/web/20100312044640/http://www.vical.com/products/cancer_therapies/allovectin-7.htm |archivedate=2010-03-12 ))</ref> and BioVex’s OncoVex (28% CR + PR),<ref name="OncoVex">((cite web|url=http://www.biovex.com/downloads/ASCO_melanoma_poster_2009.pdf|title=OncoVex Phase II data|access-date=2009-12-21|archive-url=https://web.archive.org/web/20101026100138/http://www.biovex.com/downloads/ASCO_melanoma_poster_2009.pdf|archive-date=2010-10-26|url-status=dead))</ref> both of which are given as stand alone therapy.

Due to the [[Financial crisis of 2007–2010]] and recent cancer vaccine failures in other companies like Favrille and Cell Genesys, Avax has had trouble attracting investors. In an effort to conserve cash, enrollment for the Phase III trial was suspended on March 26, 2009,<ref name="Suspension">((cite web|url=https://www.sec.gov/Archives/edgar/data/1015441/000114420409016249/v143945_8k.htm|title=Enrollment Suspension))</ref> but the trial itself is still ongoing. However on December 16, 2009, the company obtained bridge financing in the amount of $1,400,000. This will be used to conduct an interim analysis of the Phase III data for MVax. CEO John Prendergast notes: "Recent and anticipated news by companies involved with cancer vaccines and immunotherapies has resulted in renewed interest in the sector by institutional investors, larger pharma, biotechnology companies and the medical and scientific communities at large.".<ref name="News">((cite web|url=http://www.avax-tech.com/news/2009/09_1216.php |title=December 16, 2009 news |url-status=dead |archiveurl=https://web.archive.org/web/20130501232847/http://www.avax-tech.com/news/2009/09_1216.php |archivedate=2013-05-01 ))</ref>

====LVax====
Started February 2006. Currently in a Phase I/II trial for [[NSCLC]].((Citation needed|date=January 2020)) No new patient enrollment until more funding is obtained.

====OVax====
Started April 2008, a Phase I/II trial for [[ovarian cancer]]. Encouraging results reported Feb 2016.<ref name=ovax-feb2016>[http://immuno-oncologynews.com/2016/02/03/avax-technologies-announces-results-of-its-ovax-ovarian-cancer-vaccine-phase-12-clinical-trial-in-patients-with-relapsed-stage-iii-or-iv-ovarian-cancer/ Advanced Ovarian Cancer Treatment Showing Promise in Clinical Trial. Feb 2016]</ref> Median survival was 22.7 months with no treatment-related serious adverse events.<ref name=ovax-feb2016/>

==Genopoietic SA==
Based in [[Lyon]], France, has a GMP facility that manufactures the vaccines for Avax. The facility is certified by the French government for commercial and clinical vaccine production for the European markets.<ref name="Avax fact sheet"/>

==See also==
*[[Dendreon]]
*[[Cancer vaccine]]

==Notes==
((reflist|2))

==External links==
((Finance links
|symbol=AVXT
|reuters=AVXT.PK
|bloomberg=AVXT:US
|sec_cik=1015441
|yahoo=AVXT
|google=AVXT:OTCMKTS
))

((Pharmaceutical companies of the United States))
((authority control))

[[Category:Companies traded over-the-counter in the United States]]
[[Category:Biotechnology companies of the United States]]
[[Category:Companies based in Philadelphia]]
[[Category:Pharmaceutical companies of the United States]]
[[Category:Companies with year of establishment missing]]
[[Category:Health care companies based in Pennsylvania]]

Pages transcluded onto the current version of this page (help):

Avax Technologies (edit)
Template:Ambox (view source) (template editor protected)
Template:Authority control (view source) (template editor protected)
Template:Category handler (view source) (protected)
Template:Citation needed (view source) (protected)
Template:Cite web (view source) (protected)
Template:Comma separated entries (view source) (template editor protected)
Template:Country data United States (view source) (template editor protected)
Template:Delink (view source) (template editor protected)
Template:Finance links (view source) (template editor protected)
Template:Find sources mainspace (view source) (template editor protected)
Template:Fix (view source) (protected)
Template:Fix/category (view source) (template editor protected)
Template:Flagicon (view source) (template editor protected)
Template:Flagicon/core (view source) (template editor protected)
Template:Hlist (view source) (template editor protected)
Template:Hlist/styles.css (view source) (protected)
Template:Infobox (view source) (template editor protected)
Template:Infobox company (view source) (template editor protected)
Template:Longitem (view source) (template editor protected)
Template:Main other (view source) (protected)
Template:More citations needed (view source) (template editor protected)
Template:Navbox (view source) (template editor protected)
Template:Nowrap (view source) (protected)
Template:OTC Expert (edit)
Template:PAGENAMEBASE (view source) (template editor protected)
Template:Pagetype (view source) (protected)
Template:Pharmaceutical companies of the United States (edit)
Template:Reflist (view source) (protected)
Template:Reflist/styles.css (view source) (protected)
Template:SDcat (view source) (template editor protected)
Template:Short description (view source) (protected)
Template:Short description/lowercasecheck (view source) (protected)
Template:Template other (view source) (protected)
Template:Verification (view source) (semi-protected)
Template:Yesno (view source) (protected)
Template:Yesno-no (view source) (template editor protected)
Module:Arguments (view source) (protected)
Module:Authority control (view source) (template editor protected)
Module:Authority control/config (view source) (template editor protected)
Module:Category handler (view source) (protected)
Module:Category handler/blacklist (view source) (protected)
Module:Category handler/config (view source) (protected)
Module:Category handler/data (view source) (protected)
Module:Category handler/shared (view source) (protected)
Module:Check for clobbered parameters (view source) (template editor protected)
Module:Check for unknown parameters (view source) (protected)
Module:Citation/CS1 (view source) (protected)
Module:Citation/CS1/COinS (view source) (protected)
Module:Citation/CS1/Configuration (view source) (protected)
Module:Citation/CS1/Date validation (view source) (protected)
Module:Citation/CS1/Identifiers (view source) (protected)
Module:Citation/CS1/Utilities (view source) (protected)
Module:Citation/CS1/Whitelist (view source) (protected)
Module:Citation/CS1/styles.css (view source) (protected)
Module:Delink (view source) (template editor protected)
Module:Disambiguation (view source) (protected)
Module:Disambiguation/templates (view source) (protected)
Module:Find sources (view source) (template editor protected)
Module:Find sources/config (view source) (template editor protected)
Module:Find sources/links (view source) (template editor protected)
Module:Find sources/templates/Find sources mainspace (view source) (template editor protected)
Module:Infobox (view source) (template editor protected)
Module:Infobox/styles.css (view source) (template editor protected)
Module:InfoboxImage (view source) (template editor protected)
Module:List (view source) (protected)
Module:Message box (view source) (protected)
Module:Message box/ambox.css (view source) (protected)
Module:Message box/configuration (view source) (protected)
Module:Namespace detect/config (view source) (protected)
Module:Namespace detect/data (view source) (protected)
Module:Navbar (view source) (protected)
Module:Navbar/configuration (view source) (protected)
Module:Navbar/styles.css (view source) (protected)
Module:Navbox (view source) (template editor protected)
Module:Navbox/configuration (view source) (template editor protected)
Module:Navbox/styles.css (view source) (template editor protected)
Module:Pagetype (view source) (protected)
Module:Pagetype/config (view source) (protected)
Module:Redirect (view source) (protected)
Module:SDcat (view source) (template editor protected)
Module:Separated entries (view source) (protected)
Module:String (view source) (protected)
Module:TableTools (view source) (protected)
Module:Unsubst (view source) (protected)
Module:WikidataIB (view source) (template editor protected)
Module:WikidataIB/nolinks (view source) (template editor protected)
Module:WikidataIB/titleformats (view source) (template editor protected)
Module:Yesno (view source) (protected)

Return to Avax Technologies.

Retrieved from "https://en.wikipedia.org/wiki/Avax_Technologies"